Oruka Therapeutics, Inc.
ORKA
$29.57
$1.746.23%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 20.62M | 19.26M | 17.74M | 12.58M | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 125.08M | 120.42M | 113.48M | 95.26M | -- |
| Operating Income | -125.08M | -120.42M | -113.48M | -95.26M | -- |
| Income Before Tax | -109.24M | -107.59M | -105.26M | -84.26M | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -109.24 | -107.59 | -105.26 | -84.26 | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -109.24M | -107.59M | -105.26M | -91.34M | -- |
| EBIT | -125.08M | -120.42M | -113.48M | -95.26M | -- |
| EBITDA | -125.00M | -120.36M | -91.95M | -66.88M | -- |
| EPS Basic | -1.94 | -2.86 | -9.35 | -24.13 | -- |
| Normalized Basic EPS | -1.57 | -2.33 | -6.32 | -6.00 | -- |
| EPS Diluted | -1.94 | -2.86 | -9.35 | -24.13 | -- |
| Normalized Diluted EPS | -1.57 | -2.33 | -6.32 | -6.00 | -- |
| Average Basic Shares Outstanding | 171.70M | 142.65M | 103.75M | 62.07M | -- |
| Average Diluted Shares Outstanding | 171.70M | 142.65M | 103.75M | 62.54M | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |